Typical weight loss drugs in late-stage human clinical trials showed only about 10% weight loss in the most successful studies. We acknowledge that the data generated with OXY-RPEG thus far is early-stage, but we would point out that if 30% weight loss can be replicated in human studies, this agent would easily be the most effective weight loss therapy available. Currently, we expect oxyntomodulin Phase 1 studies to commence in late 2012, following the completion of the preclinical assessments necessary to file an Investigational New Drug (IND) application with the US FDA. Development of the drug is likely to take several years after that, even in conjunction with a partner.
OPKO Announces Presentation of Data on Long-Acting Oxyntomodulin at Diabetes Conference
MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) today announced that it will present data on its long acting oxyntomodulin (MOD-6030) product on April 25, 2014 at the 7th Diabetes Drug Discovery and Development Conference being held in Cambridge, MA. Company scientists will make an oral presentation discussing MOD-6030, the company’s long-acting GLP-1 and Glucagon dual agonist with potential for the treatment of type 2 diabetes and obesity. Pre-clinical data shows the drug induced a marked weight loss and food intake inhibition in both animal models which were superior compared to those with bi-daily injections of native OXM and to bi-daily injections of existing marketed drugs